Ventilator-Associated Pneumonia
- J. Chastre, J. Fagon
- Medicine, BiologyPerspectives on Critical Care Infectious Diseases
- 1 May 2001
Appropriate antimicrobial treatment of patients with VAP significantly improves outcome, more rapid identification of infected patients and accurate selection of antimicrobial agents represent important clinical goals.
Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.
- J. Chastre, M. Wolff, S. Aubas
- MedicineJAMA
- 19 November 2003
Although patients with VAP caused by nonfermenting gram-negative bacilli, including Pseudomonas aeruginosa, did not have more unfavorable outcomes when antimicrobial therapy lasted only 8 days, they did have a higher pulmonary infection-recurrence rate compared with those receiving 15 days of treatment.
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial
- L. Bouadma, C. Luyt, M. Wolff
- MedicineThe Lancet
- 6 February 2010
Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.
- J. Trouillet, J. Chastre, C. Gibert
- Medicine, BiologyAmerican Journal of Respiratory and Critical Care…
- 1 February 1998
Differences in the potential efficacies against microorganisms of 15 antimicrobial regimens were studied to provide a more rational basis for selecting the initial therapy of patients suspected of having VAP.
Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.
- R. Wunderink, M. Niederman, J. Chastre
- Medicine, BiologyClinical Infectious Diseases
- 1 March 2012
Clinical response at EOS in the PP population was significantly higher with linezolid than with vancomycin, although 60-day mortality was similar, and survival and safety were also evaluated.
International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia
- A. Torres, M. Niederman, R. Wunderink
- MedicineEuropean Respiratory Journal
- 1 September 2017
The panel selected seven PICO (population–intervention–comparison–outcome) questions that generated a series of recommendations for HAP/VAP diagnosis, treatment and prevention that were adopted by the ERS/ESICM/ESCMID/ALAT panel.
The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome
- M. Schmidt, E. Zogheib, A. Combes
- Medicine, PsychologyIntensive Care Medicine
- 2 August 2013
The PRESERVE score might help ICU physicians select appropriate candidates for ECMO among severe ARDS patients and future studies should also focus on physical and psychosocial rehabilitation that could lead to improved HRQL in this population.
Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated Pneumonia
- J. Fagon, J. Chastre, A. Tenaillon
- MedicineAnnals of Internal Medicine
- 18 April 2000
To test the hypothesis that an invasive management strategy is superior to a clinical, noninvasive one in terms of improving clinical outcomes and minimizing antibiotic use, a multicenter, randomized, uncontrolled trial is initiated to compare these strategies in patients suspected of having ventilator-associated pneumonia.
Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation.
- C. Luyt, A. Combes, J. Chastre
- Medicine, BiologyAmerican Journal of Respiratory and Critical Care…
- 1 May 2007
HSV bronchopneumonitis is common in nonimmunocompromised patients with prolonged mechanical ventilation, is associated with HSV reactivation or infection of the mouth and/or throat, and seems to be associated with poorer outcome.
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study*
- J. Chastre, R. Wunderink, P. Prokocimer, Michael Lee, K. Kaniga, I. Friedland
- Medicine, BiologyCritical Care Medicine
- 1 April 2008
In this large, phase III study of patients with ventilator-associated pneumonia, a 4-hr intravenous infusion of doripenem was clinically efficacious and therapeutically noninferior to imipenems.
...
...